BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Significant pleural effusion

CNS metastases by head CT scan or MRI within the past 4 weeks

Pregnant or breast-feeding

Prior chemotherapy or monoclonal antibodies for other cancers within 5 years prior to registration

Prior chemotherapy for lung cancer

Prior chest radiotherapy

Ongoing (lasting \> 14 days) or active infection or ongoing (lasting \> 14 days) fever within the past 6 months

Gross hemoptysis ≥ grade 2 (defined as ≥ ½ teaspoon of bright red blood per episode) within the past 3 months

Bleeding ≥ grade 2 or any bleeding requiring intervention

Clinically significant cardiovascular disease

Myocardial infarction within the past 6 months

New York Heart Association class III-IV congestive heart failure

Unstable angina pectoris

Serious cardiac arrhythmia requiring medication within the past 4 weeks

History of hypertensive crisis or hypertensive encephalopathy

Stroke or transient ischemic attack within the past 6 months

Peripheral vascular disease ≥ grade 2 within the past 6 months

Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months

Psychiatric illness or social situation that would limit compliance with study requirements

History of uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg) while on stable regimen of antihypertensive therapy

Significant traumatic injury or serious non-healing wound, ulcer, or bone fracture within the past 4 weeks

Concurrent major surgical procedure

Having anticipated major surgical procedure(s) during the course of the study

Concurrent daily aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory agents (NSAIDs) known to inhibit platelet function

Recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital immunodeficiencies

Pre-existing medical condition requiring chronic steroids or immunosuppressive therapy

Autoimmune disease

Known hepatitis B or C

Immunotherapy (e.g., interferon, interleukin, sargramostim \[GM-CSF\], or filgrastim \[G-CSF\]) within 28 days prior to registration

Prior splenectomy

Hypersensitivity to any component of bevacizumab

Prior core biopsy or any other minor surgical procedure, excluding the placement of a vascular access device, within 7 days prior to registration

Progressive disease or unevaluable disease per RECIST criteria upon post- consolidation chemotherapy evaluation

Autoimmune disease

What this study is about